Suppression of allograft rejection is central to successful organ transplantation; thus,
immunosuppressive agents are crucial for successful allograft function. Immunosuppressive …

Mycophenolate mofetil (MMF, CellCept®) is a prodrug of mycophenolic acid (MPA), an
inhibitor of inosine monophosphate dehydrogenase (IMPDH). This is the rate-limiting …

The pharmacokinetics of the immunosuppressant mycophenolate mofetil have been
investigated in healthy volunteers and mainly in recipients of renal allografts. Following oral …

Context Current remission maintenance therapies for antineutrophil cytoplasmic antibody
(ANCA)–associated vasculitis (AAV) are limited by partial efficacy and toxicity. Objective To …

Background Long-term administration of cyclosporin carries a risk of renal toxicity, and
immunosuppressants are associated with an increased rate of malignant disorders. We …

This review aims to provide an extensive overview of the literature on the clinical
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …

Background. To confirm the results of a number of studies conducted in Europe, the United
States, and Japan, this multicenter, randomized trial compared the 12-month efficacy and …

Background Currently available immunosuppressive regimens for cadaver-kidney recipients
are far from ideal because acute-rejection episodes occur in about 30% to 50% of these …

Background. After heart transplantation, 1-year and 5-year survival rates are 79% and 63%,
respectively, with rejection, infection, and allograft coronary artery disease accounting for the …

Cardiovascular disease is one of the major causes of morbidity and mortality following solid
organ transplantation. Many of the current immunosuppressive drugs are associated with an …